Related Experiment Videos
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and
A Dørum1, P Møller, E J Kamsteeg
1Department of Oncology, Norwegian Radium Hospital, Oslo, Norway.
European Journal of Cancer (Oxford, England : 1990)
|June 9, 1998
Summary
Researchers identified a specific BRCA1 founder mutation (1675delA) in Norwegian breast/ovarian cancer families. This finding aids genetic counseling and understanding founder effects in inherited diseases.
Area of Science:
- Genetics
- Oncology
- Population Studies
Background:
- Breast and ovarian cancers are often linked to hereditary factors.
- Identifying founder mutations is crucial for understanding disease prevalence in specific populations.
Purpose of the Study:
- To identify a founder mutation for breast/ovarian cancer in a Norwegian population.
- To assess the prevalence and implications of the identified mutation.
Main Methods:
- Haplotype analysis of markers near the BRCA1 gene.
- Screening of 33 breast/ovarian cancer families.
- Protein truncation test (PTT) for exon 11 mutations.
Main Results:
- A shared haplotype was found in 39.4% of affected individuals.
- The 1675delA BRCA1 mutation was identified in 15% of families.
- This mutation appears to be the primary founder mutation in the studied region.
Conclusions:
- The 1675delA mutation represents a significant founder effect in this Norwegian population.
- This finding facilitates precise genotype-phenotype correlation for genetic counseling.
- Haplotype analysis can estimate founder effects for other genetic diseases.